Wedbush analyst David Nierengarten maintained an Outperform rating and $103 price target on Blueprint Medicines after the company presented data from its avapritinib Phase 1 NAVIGATOR study in gastrointestinal stromal tumor patients at the Connective Tissue Oncology Society annual meeting. In a research note to investors, Nierengaren says avapritinib continues to show best in class efficacy in PDGFRalpha D842V GIST patients with an overall response rate of 84% regardless of treatment line and a significant ORR for greater than or equal to4L GIST patients irrespective of mutation and views these results and supportive safety data as sufficient for Blueprint to proceed with their intended NDA filing in 1H19 for PDGFRalpha D842V and greater than or equal to4L GIST patients.